DALLAS, Nov. 4, 2021 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence ("A.I.")
platform to transform the cost, pace, and timeline of oncology drug
discovery and development, today announced that Lantern Pharma's
abstract on the effectiveness of LP-284 in hematologic cancers has
been accepted as a poster at the upcoming 63rd American
Society of Hematology (ASH) Annual Meeting, which is being held
in-person and virtually from December
11 – 14, 2021. The abstract is available online on the ASH
website.
Abstract Title: The Positive Enantiomer of a Novel Chiral
DNA Alkylating Agent Exhibits Nanomolar Potency in Hematologic
Cancers
Session Name: 802. Chemical Biology and Experimental
Therapeutics: Poster III
Abstract Number: 3991
Poster Session Date & Time: Monday, December 13, 2021, 6:00 PM - 8:00 PM
Presenter: Jianli Zhou,
Ph.D., Lantern Pharma
LP-284 is a fully synthetic molecule belonging to the new
generation of acylfulvenes, a family of naturally derived
anti-cancer drug candidates. While LP-184 shows potency in solid
cancer, LP-284 was primarily developed as an analogue which shows
selective efficacy against hematologic cancer. LP-284 is currently
being evaluated for activity in a wide spectrum of hematological
cancers.
Together with the work of collaborators, the roadmap to
advancement of LP-284 to the clinic includes identification and
validation of target indications, response gene signature
development leading to IND-enabling pharmacokinetic profiling, and
tolerability and dose range finding studies followed by clinical
protocol development.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary RADR® A.I.
platform and machine learning to discover biomarker signatures that
identify patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across eight disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and Twitter
@lanternpharma.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and patient
populations that are likely to respond to a drug candidate; our
strategic plans to advance the development of our drug candidates
and antibody drug conjugate (ADC) development program; estimates
regarding the development timing for our drug candidates and ADC
development program; our research and development efforts of our
internal drug discovery programs and the utilization of our
RADR® platform to streamline the drug development process; our
intention to leverage artificial intelligence, machine learning and
genomic data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding potential markets and potential market sizes;
sales estimates for our drug candidates and our plans to discover
and develop drug candidates and to maximize their commercial
potential by advancing such drug candidates ourselves or in
collaboration with others. Any statements that are not statements
of historical fact (including, without limitation, statements that
use words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "objective," "aim,"
"upcoming," "should," "will," "would," or the negative of these
words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that our research and the
research of our collaborators may not be successful, (iii) the risk
that none of our product candidates has received FDA marketing
approval, and we may not be able to successfully initiate, conduct,
or conclude clinical testing for or obtain marketing approval for
our product candidates, (iv) the risk that no drug product based on
our proprietary RADR A.I. platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (v) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
CONTACTS:
Investor Relations
David Waldman, Crescendo
Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas Koulermos, Vice President –
5W Public Relations
lantern@5wpr.com
646-843-1812
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-abstract-on-effectiveness-of-lp-284-in-hematologic-cancers-accepted-for-presentation-at-the-63rd-american-society-of-hematology-ash-annual-meeting-301416654.html
SOURCE Lantern Pharma